retatrutide triple agonist weight loss trial just delivered the first top-line Phase 3 results for a in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide: The triple agonist powering

A large study in the BMJ published in March of more than 600,000 US veterans with Type 2 diabetes found that starting a GLP-1 was associated with a 14% lower overall risk of developing alcohol, cannabis, cocaine, nicotine, and opioid use disorders

She is a licensed pharmacist in Wisconsin and is on the Board of Directors for the National Association of Specialty Pharmacy and the Drug Selection Advisory Committee for CivicaScript

These facilities undergo strict inspections, but because the compounded pharmaceuticals they produce are made according to a prescription from a specific practitioner for a particular patient, they are not FDA-approved

Purtell advises focusing on achieving sustainable weight loss rather than fixating on a specific number on the scale

Read Guide Disclaimer: All guides are written for research and laboratory purposes only